anti-rheumatoid

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anticancer activity. It inhibits the production of IL-6 and IL-1β, induces apoptosis, and can be used to prevent inflammation and destruction of cartilage or bone. This makes Golimumab valuable for studying rheumatoid arthritis and cancer.

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Olokizumab (CDP-6038) is a humanized anti-IL-6 monoclonal antibody that selectively blocks the final assembly of the IL-6 signaling complex for the study of rheumatoid arthritis (RA).

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (mAb) that enhances T cell infiltration and strengthens antitumor immune responses. Cabiralizumab prevents osteoclast activation, thereby inhibiting bone destruction, and is employed in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab has been investigated in combination with Nivolumab in lung cancer studies, highlighting its role in immune-oncology.

Vobarilizumab (ALX-0061) is a humanized, specific monoclonal antibody targeting IL-6R and albumin (ALB), consisting of an anti-IL-6R domain and an anti-human albumin domain, used in the study of rheumatoid arthritis and other autoimmune diseases.

Adalimumab beta (ABP-501) is an anti-TNF-α monoclonal antibody used in rheumatoid arthritis (RA) research [1].

Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.

Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis.

Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.

Nipocalimab (M281) is a fully humanized anti-FcRn monoclonal antibody that can be used to study systemic myasthenia gravis and rheumatoid arthritis.

Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.

Priliximab (CEN 000029), an anti-CD4 humanized monoclonal antibody, binds to CD4 receptors on T cells, leading to a significant and sustained decrease in circulating CD4+ T cells. This property renders it useful in the study of rheumatoid arthritis (RA) [1].

ABBV-154 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized antibody Adalimumab linked to a glucocorticoid receptor modulator. It is employed in the research of rheumatoid arthritis, Crohn's disease, and polymyalgia rheumatica.

ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized TNF antibody adalimumab and a glucocorticoid receptor agonist. It is designed for use in research related to rheumatoid arthritis.

Lecankitug is a humanized monoclonal antibody that targets human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). By specifically binding to IL-17A and IL-17F, Lecankitug blocks their signaling pathways, exhibiting immunosuppressive and anti-inflammatory actions. It is a promising candidate for research in autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.

Crusekitug is a humanized monoclonal antibody that targets human interleukin 17A (IL-17A). It specifically binds to IL-17A, inhibiting its signal transduction, thereby exerting immunosuppressive and anti-inflammatory effects. Crusekitug shows potential for research in autoimmune and inflammatory diseases such as psoriasis and rheumatoid arthritis.